Methodist Cancer Center, Houston, Texas Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Houston TX United States (1919)

Organization Overview

First Clinical Trial
1993
NCT00058812
First Marketed Drug
2015
fludeoxyglucose f-18
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Ahmed Osama Gaber, MD | Ashley Holder, MD | Breast Medical Oncologist, Methodist Cancer Center, Houston, Texas | Clinical Trial Network | David Baskin MD | Houston Methodist | Houston Methodist Cancer Center | Houston Methodist Centers of Performing Arts Medicine | Houston Methodist Gastroenterology Associates | Houston Methodist Gastroenterology Clinical Research Foundation, Houston, Texas | Houston Methodist Hosptial | Houston Methodist Neurological Institute | HOUSTON METHODIST NEUROLOGICAL INSTITUTE | Houston Methodist Physicians Organization | Jenny C. Chang, MD | Jorge G. Darcourt | METHODIST | Methodist Cardiovascular Surgery Associates | Methodist DeBakey Heart Center. | Methodist DeBakey Heart Center, Houston TX, USA | Methodist Hospital - Texas Transplant Institute | METHODIST HOSP RES | Methodist Neurological Institute | Methodist Neurological Institute, Houston | Rose Khavari, M.D. | Stanley H. Appel, MD | The Methodist Hospital System | William Ondo, MD